Migraines are a common ailment worldwide, affecting nearly 15% of the global population. At times, they can be debilitating ...

Innovation in obesity treatments, Alzheimer's detection and medical-device applications is setting the stage for a number of ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

Novo Nordisk executives overlooked warnings ahead of Wegovy's launch, leading to supply issues, high costs, and challenges competing with Eli Lilly's Zepbound.

The Grammy-nominated musicians discuss what's helping them manage, and why they’re using their platform to reach the Black ...

Semaglutide- the active ingredient in 'Wegovy' and 'Ozempic'- may lower dementia risk in people with type 2 diabetes. | Drug ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

“My vision is that every American is wearing a wearable within four years,” he said at a congressional hearing last week. It ...

A drug that can be taken orally could soon rival the likes of Ozempic for treating type 2 diabetes and obesity, according to ...

COPENHAGEN (Reuters) -Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared ...

GLP-1 drugs like Ozempic® and Zepbound®, have gained significant attention in recent years for treating both diabetes and ...

A UCSF analysis has found that the newer generation of much more effective diabetes medications are reaching only a fraction of the patients who are recommended to take them based on new guidelines.